| Overview |
| bsm-70401M |
| CD55 (Extracellular region) Antibody |
| WB, IP, ICC |
| Clone M002 detects 60-80 kDa* bands corresponding to the molecular mass of CD55 on SDS-PAGE immunoblots of "native" A431, A549, and MDA-MB-231 cell lysates. The antibody also detects a "native" recombinant human CD55 extracellular region, but does not detect the denatured form of CD55. The antibody works for native western blot, immunoprecipitation, protein ELISA, and immunocytochemistry. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Clone M002 was generated from proprietary antigen related to the extracellular region of human CD55 from the MDA-MB-231 breast cancer cell line. |
| Monoclonal |
| M002 |
| IgG2a |
| Purified by Protein G. |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| P08174 |
| Complement decay-accelerating factor, DAF,
CD_antigen, CD55, CR |
| CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients. |
| Application Dilution |
| WB |
1:300-5000 |
| IP |
1-2ug |
| ICC |
1:100-500 |
Powered by Bioz